These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 39158844

  • 1. Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons.
    Jiang T, Shanmugasundaram M, Božin I, Freedman MS, Lewin JB, Shen C, Ziemssen T, Arnold DL.
    J Comp Eff Res; 2024 Oct; 13(10):e230161. PubMed ID: 39158844
    [Abstract] [Full Text] [Related]

  • 2. Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis.
    Jiang T, Ziemssen T, Wray S, Shen C, Söderbärg K, Lewin JB, Božin I, Freedman MS.
    CNS Drugs; 2023 May; 37(5):441-452. PubMed ID: 37155132
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, RADIANCE Trial Investigators.
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [Abstract] [Full Text] [Related]

  • 4. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S, Kumar J, Arndorfer S, Zhu X, Zivkovic M, Tencer T.
    CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
    [Abstract] [Full Text] [Related]

  • 5. Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study.
    Bowen JD, Stulc J, Hunter SF, Chen H, Lewin JB, Scaramozza M, Bozin I, Then Bergh F.
    Adv Ther; 2024 Aug; 41(8):3396-3406. PubMed ID: 38878121
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, SUNBEAM Study Investigators.
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
    Wray S, Then Bergh F, Wundes A, Arnold DL, Drulovic J, Jasinska E, Bowen JD, Negroski D, Naismith RT, Hunter SF, Gudesblatt M, Chen H, Lyons J, Shankar SL, Kapadia S, Mendoza JP, Singer BA.
    Adv Ther; 2022 Apr; 39(4):1810-1831. PubMed ID: 35211872
    [Abstract] [Full Text] [Related]

  • 8. Comparative effectiveness and safety of ozanimod versus other oral DMTs in relapsing-remitting multiple sclerosis: a synthesis of matching-adjusted indirect comparisons.
    Paul D, Swallow E, Patterson-Lomba O, Branchcomb T, N'Dri L, Gomez-Lievano A, Liu J, Dua A, McGinley M.
    Ther Adv Neurol Disord; 2024 Apr; 17():17562864241237856. PubMed ID: 38855023
    [Abstract] [Full Text] [Related]

  • 9. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
    Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ, Selmaj K, Bidollari I, Chen H, Hanna J, Leigh-Pemberton R, Lopez-Bresnahan M, Lyons J, Miller C, Rezendes D, Wolinsky JS, EVOLVE-MS-2 Study Group.
    CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
    [Abstract] [Full Text] [Related]

  • 10. Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial.
    Vermersch P, Scaramozza M, Levin S, Alroughani R, Deiva K, Pozzilli C, Lyons J, Mokliatchouk O, Pultz J, N'Dure F, Liu S, Badwan R, Branco F, Hood-Humphrey V, Franchimont N, Hanna J, Maghzi AH.
    JAMA Netw Open; 2022 Sep 01; 5(9):e2230439. PubMed ID: 36169959
    [Abstract] [Full Text] [Related]

  • 11. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Singer BA, Arnold DL, Drulovic J, Freedman MS, Gold R, Gudesblatt M, Jasinska E, LaGanke CC, Naismith RT, Negroski D, Oh J, Hernandez Perez MA, Selmaj K, Then Bergh F, Wundes A, Ziemssen T, Castro-Borrero W, Chen H, Levin S, Scaramozza M, Shankar SL, Wang T, Wray S.
    Mult Scler; 2023 Dec 01; 29(14):1795-1807. PubMed ID: 37905526
    [Abstract] [Full Text] [Related]

  • 12. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ, Wehr A, Tawa M, Perkin K, Leigh-Pemberton R, Hanna J, Miller C, Penner N.
    Adv Ther; 2019 Nov 01; 36(11):3154-3165. PubMed ID: 31538304
    [Abstract] [Full Text] [Related]

  • 13. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, Freedman MS, Gudesblatt M, Ziemssen T, Kandinov B, Bidollari I, Lopez-Bresnahan M, Nangia N, Rezendes D, Yang L, Chen H, Liu S, Hanna J, Miller C, Leigh-Pemberton R.
    Mult Scler; 2020 Nov 01; 26(13):1729-1739. PubMed ID: 31680631
    [Abstract] [Full Text] [Related]

  • 14. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ, Chan A, Zhang A, Xiao J, Levison D, Lewin JB, Edwards MR, Marantz JL.
    Curr Med Res Opin; 2017 Feb 01; 33(2):175-183. PubMed ID: 27733070
    [Abstract] [Full Text] [Related]

  • 15. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A, Li DKB, Cascione M, Fang J, Dangond F, Miller A.
    BMC Neurol; 2018 Sep 14; 18(1):143. PubMed ID: 30217172
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY).
    Shaygannejad V, Ashtari F, Saeidi M, Beladi Moghadam N, Ghalyanchi Langroodi H, Baghbanian SM, Abolfazli R, Ghiasian M, Ayromlou H, Asadollahzadeh E, Sabzvari A, Kafi H, Azimi Saeen A.
    Mult Scler Relat Disord; 2024 Oct 14; 90():105839. PubMed ID: 39217809
    [Abstract] [Full Text] [Related]

  • 17. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.
    Ernst FR, Barr P, Elmor R, Wong SL.
    Curr Med Res Opin; 2017 Dec 14; 33(12):2099-2106. PubMed ID: 28906152
    [Abstract] [Full Text] [Related]

  • 18. Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study.
    Singer BA, Wray S, Gudesblatt M, Bumstead B, Ziemssen T, Bonnell A, Scaramozza M, Levin S, Shanmugasundaram M, Chen H, Mendoza JP, Lewin JB, Shankar SL.
    Neurol Ther; 2024 Aug 14; 13(4):1273-1285. PubMed ID: 38935202
    [Abstract] [Full Text] [Related]

  • 19. Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week.
    Coyle PK, Shang S, Xiao Z, Dong Q, Castrillo-Viguera C.
    Mult Scler Relat Disord; 2018 May 14; 22():134-138. PubMed ID: 29679749
    [Abstract] [Full Text] [Related]

  • 20. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
    Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, Southworth H, Kappos L, Cohen JA, Ozanimod Study Investigators.
    Eur J Neurol; 2021 Nov 14; 28(11):3722-3730. PubMed ID: 34292643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.